ANANDA Scientific
ANANDA Scientific is a Colorado-based biopharmaceutical company developing CBD-based investigational drugs (Nantheia™ ATL5 and A1002N5S) using its patented Liquid Structure™ delivery platform, with six FDA-approved clinical trials in PTSD, opioid use disorder, social anxiety disorder, radiculopathic pain, and smoking cessation across NYU, UCLA, Mt. Sinai, UNMC, and Yale, plus a parallel nutraceutical OTC business distributed via Maypro Industries.
- Company typePrivate
- Founded2008
- HeadquartersGreenwood Village, United States
- Headcount51–100
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
ANANDA Scientific firmographics
Firmographics- Name
- ANANDA Scientific
- Legal name
- ANANDA Scientific Inc.
- Website
- https://anandascientific.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- ANANDA Scientific is a Colorado-based biopharmaceutical company developing CBD-based investigational drugs (Nantheia™ ATL5 and A1002N5S) using its patented Liquid Structure™ delivery platform, with six FDA-approved clinical trials in PTSD, opioid use disorder, social anxiety disorder, radiculopathic pain, and smoking cessation across NYU, UCLA, Mt. Sinai, UNMC, and Yale, plus a parallel nutraceutical OTC business distributed via Maypro Industries.
- Ownership category
- akta.pro rank
ANANDA Scientific industry classification
Industry- Product category
- Cannabinoid Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industry
- CBD/Hemp Wellness & Supplements Retail (CRANAHAC)
Keywords
Where ANANDA Scientific is headquartered
LocationHeadquarters
- HQ city
- Greenwood Village
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
ANANDA Scientific business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales
Revenue model
- Pharmaceutical / Investigational Drug Development: Revenue from pharmaceutical products is pre-commercial as ANANDA Scientific is currently in the clinical trial stage. The company is developing Nantheia™ investigational drugs (Nantheia™ A1002N5S and Nantheia™ ATL5) through FDA-approved clinical trials for PTSD, Social Anxiety Disorder, Opioid Use Disorder, Radiculopathic Pain, and Smoking Cessation. Anticipated future revenue will come from FDA-approved pharmaceutical drug sales upon successful completion of clinical trials and regulatory approval.
- Nutraceutical Over-the-Counter (OTC) Products: Growing pipeline of nutraceutical OTC products leveraging Liquid Structure™ technology for enhanced bioavailability. Products successfully launched in the US, Australia, and UK markets, with expansion planned into EU, China, Africa, and other Asian markets. Revenue generated from direct consumer sales and through distribution partners.
- Nutraceutical Ingredient Sales via Distribution Partner: Bulk ingredient sales of Liquid Structure™ CBD formulations through Maypro Industries, ANANDA's U.S. sales and distribution partner. Maypro is one of the largest global suppliers of nutraceutical ingredients, with six strategically located companies in the US, Japan and China.
Go-to-market motion3 records
Distribution channels5 records
Marketing channels5 records
ANANDA Scientific product offering
Product offeringCore offering
ANANDA Scientific develops and commercializes cannabinoid-based pharmaceutical and nutraceutical products built on its proprietary Liquid Structure™ delivery technology. The pharmaceutical business operates investigational CBD drugs (Nantheia™ ATL5 and Nantheia™ A1002N5S) through FDA-approved clinical trials at leading academic medical centers for neuropsychiatric indications including PTSD, Social Anxiety Disorder, Opioid Use Disorder, Radiculopathic Pain, and Smoking Cessation. The nutraceutical line sells bio-enhanced, taste-masked and beverage-stable CBD over-the-counter products through its own e-commerce, US distribution partner Maypro Industries, retail in Australia and the UK, and future Europe/MENA partner Benta SAS.
Product overview
ANANDA Scientific is a research-driven biopharmaceutical company developing life-changing medicines for unmet medical needs in neuropsychiatric disorders. The company's product portfolio centers on its patented Liquid Structure™ Technology platform, a drug delivery system that enhances bioavailability, consistent absorption, and shelf-life stability of cannabinoids. The two flagship investigational drug products are Nantheia™ ATL5 (100mg CBD per softgel) and Nantheia™ A1002N5S (50mg CBD per softgel), both leveraging the Liquid Structure™ technology and currently undergoing multiple FDA-approved clinical trials for PTSD, Social Anxiety Disorder, Opioid Use Disorder, Radiculopathic Pain, and Smoking Cessation. The company also maintains a growing pipeline of nutraceutical over-the-counter products.
Differentiator
Problem solved
Functional benefit
Brands
- Nantheia™ ATL5: Pharmaceutical Grade Cannabidiol Isolate combined with Liquid Structure™ Technology; 100mg CBD per softgel; under evaluation in clinical trials for PTSD, Social Anxiety Disorder, and Opioid Use Disorder.
- Nantheia™ A1002N5S
Products and services
- Nantheia™ ATL5 Pharmaceutical-grade investigational drug combining 100mg Pharmaceutical Grade Cannabidiol Isolate per softgel with ANANDA's patented Liquid Structure™ delivery technology in soft gelatin capsules. Currently under evaluation in multiple FDA-approved clinical trials for PTSD, Social Anxiety Disorder, Opioid Use Disorder, Radiculopathic Pain, and Smoking Cessation at NYU, UCLA, Mt. Sinai, UNMC, and Yale.
- Nantheia™ A1002N5S Pharmaceutical-grade investigational drug combining 50mg Cannabidiol Isolate per softgel with ANANDA's patented Liquid Structure™ delivery technology in soft gelatin capsules. Currently under evaluation in multiple FDA-approved clinical trials at NYU Grossman School of Medicine for PTSD, Social Anxiety Disorder, and Radiculopathic Pain as an opioid-sparing treatment.
- Taste-Masked CBD Formulation Water-stable, high-bioavailability Liquid Structure™ CBD nutraceutical product with proprietary molecular-level taste-masking that places CBD constructs inside unique molecular envelopes to hide the characteristic bitter taste from taste buds, while maintaining water solubility suitable for beverages, tinctures, and sublingual preparations.
- Beverage-Stable CBD Formulation Water-stable Liquid Structure™ CBD nutraceutical formulation that stays in solution for years in plastic, glass, and aluminum packaging without adhering to container walls, designed for beverage, tincture, and sublingual applications and protected by US Patents 7,182,950 and 10,149,824.
Quantifiable outcome
- Pre-clinical and initial clinical studies demonstrate that Liquid Structure™ delivery technology enhances the effectiveness and stability of CBD
- +5 more outcomes
Companies that use ANANDA Scientific
Customer profileNamed customers7 records
Segments3 records
Ideal customer profiles3 records
ANANDA Scientific technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
ANANDA Scientific partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered minor and core.
- Benta SAS (France)minorMOU signed with Benta SAS, a France-based pharmaceutical company, to explore collaboration for accelerating development and future availability of Nantheia™ for PTSD treatment in Europe and the MENA region. ANANDA will lead all aspects of clinical development while Benta will focus on manufacturing expertise and infrastructure for potential future product scale-up and regional distribution.
- Yale School of MedicinecoreClinical trial evaluating Nantheia™ ATL5 co-administered with THC for treating co-occurring Opioid Use Disorder and Chronic Pain (NCT06544291), led by Joao P. De Aquino MD, Director of the Pain and Addiction Interaction Neurosciences (PAIN) Laboratory. Randomized, double-blind, placebo-controlled, cross-over study with participants maintained on stable methadone doses. Funded by NIDA.
- University of Nebraska Medical Center (UNMC)corePhase II clinical trial evaluating Nantheia™ ATL5 for PTSD with 240 participants planned (NCT05269459), led by Mathew Rizzo MD. FDA IND approved. The trial has a diverse team spanning neuroscience, psychiatry, neuroimaging, and public policy. This is ANANDA's second PTSD trial, allowing comparison with NYU's Nantheia™ A1002N5S trial.
- Icahn School of Medicine at Mt. SinaicorePhase I trial completed at Mt. Sinai evaluating pharmacokinetic profile, safety, and drug tolerability of Nantheia™ ATL5 versus Epidiolex™ in 24 subjects for Opioid Use Disorder (NCT05023070), led by Yasmin L Hurd PhD, Ward-Coleman Chair of Translational Neuroscience and Director of the Addiction Institute at Mount Sinai. Funded by NIDA.
- Geffen School of Medicine at UCLAcoreClinical trial collaboration with the Jane and Terry Semel Institute at UCLA for: (1) Phase I/II trial evaluating Nantheia™ ATL5 as adjunctive treatment for Opioid Use Disorder (NCT03787628), led by Edythe London PhD and Richard De La Garza II PhD; (2) Clinical trial for smoking cessation evaluating Nantheia™ ATL5 800mg CBD daily for 8 weeks (NCT06218056), led by Edythe London PhD. Funded by NIDA and Center for Medicinal Cannabis Research.
- NYU Grossman School of MedicinecoreMultiple clinical trial collaborations: (1) Phase II trial evaluating Nantheia™ A1002N5S for PTSD with 120 participants (NCT04550377), led by Charles Marmar MD and Esther Blessing MD PhD; (2) Phase II trial for Social Anxiety Disorder with 60 participants (NCT05571592), led by Naomi Simon MD MSc and Esther Blessing MD PhD; (3) Trial evaluating Nantheia™ A1002N5S for opioid-sparing in radiculopathic pain (NCT04760613), led by Stephen Ross MD. Funded in part by NCCIH/NIH.
- Maypro IndustriescoreAppointment of Maypro Industries as ANANDA's U.S. sales and distribution partner for bulk nutraceutical ingredient products. Maypro is one of the largest global suppliers of nutraceutical ingredients, with six strategically located companies in the US, Japan and China, and a highly selective portfolio of patented and branded ingredients backed by clinical data.
- Lyotropic Delivery Systems (LDS) Ltd. (Jerusalem, Israel)coreLicensing agreement for Liquid Structure™ delivery technology from Lyotropic Delivery Systems (LDS) Ltd. and The Hebrew University of Jerusalem. LDS founder Professor Nissim Garti is the inventor of the technology. ANANDA uses this patented technology across its entire pharmaceutical and nutraceutical product portfolio. Pre-clinical and initial clinical studies show the technology enhances the effectiveness and stability of CBD.
- Hadassah Medical Hospital (Jerusalem, Israel)coreClinical collaboration with Hadassah Medical Hospital for Phase I human clinical trial assessing bioavailability and safety of ANANDA's Liquid Structure™ CBD formulation versus CBD in olive oil. Completed in 2020. Additional preclinical studies exploring modes of action for Liquid Structure™ formulations were completed in 2022. Hadassah Clinical Research Center is a leading early-phase clinical facility in Israel.
- University of FloridaminorPreclinical studies with proprietary Liquid Structure™ cannabinoid formulations to further understand the mode of action of the proprietary formulations in the body, led by Mark Kindy PhD.
Scale indicators7 records
Recent moves7 records
Expansion highlights6 records
ANANDA Scientific competitors and assessment
Company assessmentBroad incumbents
- Jazz Pharmaceuticals: Acquired GW Pharmaceuticals in 2021 for ~$7.2B, making it the owner of Epidiolex®, the first FDA-approved CBD therapeutic and a direct comparator to ANANDA's Nantheia™ programs in CNS indications. Most direct commercial benchmark for ANANDA's pharmaceutical ambitions.
- Sage Therapeutics: Specialty CNS biopharmaceutical company focused on neuropsychiatric disorders including depression and epilepsy. Comparable business model targeting CNS indications with novel mechanisms, providing a relevant benchmark for ANANDA's specialty pharma positioning.
- Canopy Growth Corporation: Large-scale cannabis company with pharmaceutical R&D division. Comparable in pursuing cannabinoid-based pharmaceutical development, though broader cannabis industry exposure makes it a broader market incumbent rather than a focused CBD therapeutics peer.
Direct peers
- Zynerba Pharmaceuticals: Clinical-stage cannabinoid therapeutics company developing transdermal CBD for Fragile X syndrome and other neuropsychiatric conditions. Closest direct peer in cannabinoid CNS drug development, though focused on different delivery (transdermal vs. oral softgel) and indications.
- Marinus Pharmaceuticals: Specialty pharmaceutical company developing CNS therapeutics including ganaxolone for seizure disorders. Comparable clinical-stage CNS biopharma with FDA-approved product (Ztalmy®), relevant as a benchmark for ANANDA's regulatory and commercial pathway in CNS.
- Charlotte's Web Holdings: Leading CBD wellness and nutraceutical brand with established US retail distribution. Most direct comparable in ANANDA's nutraceutical OTC business, with similar target consumer segments and product positioning in premium CBD wellness.
- CV Sciences: Specialty CBD consumer products company with PlusCBD™ brand and pharmaceutical R&D division developing CBD-based therapeutics. Combines consumer nutraceutical business with pharmaceutical development, closely mirroring ANANDA's dual business model.
Emerging players
- PurePlay Capital / Tetra Bio-Pharma: Canadian cannabinoid-derived pharmaceutical company developing prescription cannabinoid drugs. Comparable emerging player in cannabinoid drug development with regulatory pathway focus, relevant peer for ANANDA's pharmaceutical business unit.
Others
- Lyotropic Delivery Systems (LDS): Israel-based licensor of the Liquid Structure™ technology to ANANDA. As the technology partner, LDS is an ecosystem participant rather than a competitor, but provides relevant context on the platform's underlying scientific foundation.
- Maypro Industries: US distribution partner for ANANDA's bulk nutraceutical ingredients. As a major nutraceutical ingredient distributor serving similar wellness brands, Maypro is a channel partner and ecosystem participant relevant to ANANDA's go-to-market infrastructure.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks4 records
Key highlights7 records
Customer concentration
ANANDA Scientific social profiles
Digital presenceANANDA Scientific compliance and trust
Trust signalCompliance4 records
ANANDA Scientific financial estimates
Financial estimateRevenue estimate
Valuation estimate
ANANDA Scientific leadership team
Management profileNumber of profiles
Profiles19 records
ANANDA Scientific funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ANANDA Scientific M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ANANDA Scientific
What does ANANDA Scientific do?
ANANDA Scientific develops and commercializes cannabinoid-based pharmaceutical and nutraceutical products built on its proprietary Liquid Structure™ delivery technology. The pharmaceutical business operates investigational CBD drugs (Nantheia™ ATL5 and Nantheia™ A1002N5S) through FDA-approved clinical trials at leading academic medical centers for neuropsychiatric indications including PTSD, Social Anxiety Disorder, Opioid Use Disorder, Radiculopathic Pain, and Smoking Cessation. The nutraceutical line sells bio-enhanced, taste-masked and beverage-stable CBD over-the-counter products through its own e-commerce, US distribution partner Maypro Industries, retail in Australia and the UK, and future Europe/MENA partner Benta SAS.
Is ANANDA Scientific a public or private company?
ANANDA Scientific is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was ANANDA Scientific founded?
ANANDA Scientific was founded in 2008. It employs 51 to 100 people.
Where is ANANDA Scientific based?
ANANDA Scientific is headquartered in Greenwood Village, United States, in the North America region.
How does ANANDA Scientific make money?
Three revenue lines are on record. Pharmaceutical / Investigational Drug Development is the primary driver. The others are nutraceutical Over-the-Counter (OTC) Products and nutraceutical Ingredient Sales via Distribution Partner.
Who are ANANDA Scientific's main competitors?
Broad incumbents on record are Jazz Pharmaceuticals, Sage Therapeutics and Canopy Growth Corporation. Direct peers are Zynerba Pharmaceuticals, Marinus Pharmaceuticals, Charlotte's Web Holdings and CV Sciences. PurePlay Capital / Tetra Bio-Pharma is listed as an emerging player. Others are Lyotropic Delivery Systems (LDS) and Maypro Industries.
Does ANANDA Scientific have an API?
No public API is recorded for ANANDA Scientific.
What industry is ANANDA Scientific in?
ANANDA Scientific's product category is Cannabinoid Pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of CRANAHAC, CBD/Hemp Wellness & Supplements Retail. Its NAICS code is 325412 and its SIC code is 2834.